Article
Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening.
Pediatric pulmonology - 1 Aug 2015
Kay Denise M, Langfelder-Schwind Elinor, DeCelie-Germana Joan, Sharp Jack K, Maloney Breanne, Tavakoli Norma P, Saavedra-Matiz Carlos A, Krein Lea M, Caggana Michele, Kier Catherine
Abstract excerpt
Newborn screening for Cystic Fibrosis (CF) began in New York in October, 2002 using immunoreactive trypsinogen (IRT)/DNA methodology. Infants with at least one CFTR mutation or very high IRT and no mutations (VHIRT) are referred for sweat testing. In a preliminary analysis, we noted a very low positive predictive value (PPV) and preponderance of Hispanic infants in the group of infants with CF referred for VHIRT,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.